Gevorg Tamamyan Joins The London Global Cancer Week Steering Group
London Global Cancer Week shared a post on LinkedIn:
”London Global Cancer Week is absolutely delighted to share some important news.
We are honoured to welcome Prof Gevorg Tamamyan to the London Global Cancer Week (LGCW) Steering Group.
Prof Gevorg Tamamyan, MD, MSc, PhD, DSc, FASCO is the Co-Founder and Editor-in-Chief of OncoDaily, the world’s largest oncology media platform, created to democratize access to reliable, independent, and evidence-based cancer information globally.
Under his leadership, OncoDaily has evolved into a trusted global reference in oncology and is currently expanding into additional medical disciplines, with a strategic plan to develop up to 50 specialised health channels over the next five years.
Prof Tamamyan was elected and currently serves as President of the International Society of Pediatric Oncology (SIOP) Asia Continental Branch, representing pediatric oncology professionals across Asia, and the Pediatric Oncology East and Mediterranean (POEM) Group, uniting 28 countries and 110 cancer centres.
He is a Professor and Chairman of Haematology and Paediatric Oncology at Yerevan State Medical University, CEO of the Immune Oncology Research Institute, and adviser to the University’s Rector.
Educated and trained across seven countries in Europe, North America, and Asia, he has a professional trajectory spanning frontline clinical practice, research, academic leadership, national centre executive leadership, global health diplomacy, and institution building.
From the early days of LGCW, OncoDaily has been a powerful supporter of our mission. By amplifying our work, highlighting key discussions and bringing global attention to the conversations happening in London and beyond, Gevorg and his team have helped extend our reach far beyond the room.
As LGCW continues to grow, we are being very intentional about the people who help shape its future. Strengthening our Steering Group with leaders who bring a truly global outlook is an important part of that journey.
Gevorg brings not only an exceptional understanding of the international oncology landscape, but also a deep commitment to collaboration, knowledge sharing and global engagement in cancer care.
His presence on the Steering Group will help us continue to expand the reach, relevance and impact of London Global Cancer Week.
For us, this is both a proud moment and an important step forward.
It is a privilege to have Gevorg join the leadership of this growing global movement.
Welcome to the Steering Group, Gevorg! We are very glad to have you with us.
Find out more about our Steering Group.
Keep your diaries open for this year’s LGCW, which runs from 2nd – 6th November 2026.
This year’s focus is on Global Partnerships. Please contact us if you are interested in sponsorship.
Dr Olubukola Ayodele and Dr Susie Stanway
Co-Convenors of London Global Cancer Week”
Gevorg Tamamyan, Editor-in-Chief of OncoDaily, and the President of SIOP Asia and POEM Group, shared London Global Cancer Week‘s post on LinkedIn:
” It is a great honor and a pleasure for me
Thanks a lot, Susie Stanway and Dr Olubukola Ayodele”
Stay updated with Hemostasis Today.
-
Mar 7, 2026, 15:36Kenneth Monaghan: Empowering Stroke Survivors’ Self-Efficacy Through Neuroplasticity and Daily Activity
-
Mar 7, 2026, 15:31Tagreed Alkaltham: Practical Strategies for Navigating Blood Shortage Periods
-
Mar 7, 2026, 15:28Philip Wells Honored with the 2026 ISTH Esteemed Career Award
-
Mar 7, 2026, 15:27Gashaw Arega: A Challenging Case of Acute Immune Thrombocytopenia in an Adolescent
-
Mar 7, 2026, 15:25Worldwide Media Amplifies Call for Equity in Bleeding Disorders Care – WFH
-
Mar 7, 2026, 15:19Jecko Thachil: Can We Use Styptics as Topical Haemostats in Bleeding Disorders
-
Mar 7, 2026, 15:10Mrunalini Dandamudi: Perspective on Drug Coated Balloons in Coronary In-Stent Restenosis
-
Mar 7, 2026, 15:05Isabelle Mahé: Cancer Site, Bleeding Risk, and Reduced-Dose Apixaban in Cancer-Associated Thrombosis
-
Mar 7, 2026, 14:58Nicole Juffermans: Comparing the Effect of Plasma Versus Clear Fluids on Intravascular Volume